Mitchell Stephen Ray 4
4 · Vanda Pharmaceuticals Inc. · Filed Jun 17, 2021
Insider Transaction Report
Form 4
Mitchell Stephen Ray
Director
Transactions
- Sale
Common Stock
2021-06-15$19.42/sh−5,000$97,122→ 9,215 total - Exercise/Conversion
Common Stock
2021-06-15$10.57/sh+4,015$42,439→ 14,215 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-15−4,015→ 5,985 totalExercise: $10.57Exp: 2030-06-10→ Common Stock (4,015 underlying)
Footnotes (3)
- [F1]A portion of the shares was sold to satisfy the exercise price of the stock option and the tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021.